Septerna (NASDAQ:SEPN) SVP Daniel Long Sells 15,000 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,423,590.12. The trade was a 13.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Septerna Stock Performance

Shares of Septerna stock opened at $36.05 on Thursday. The firm has a market cap of $1.63 billion, a P/E ratio of -44.51 and a beta of 2.39. Septerna, Inc. has a twelve month low of $10.26 and a twelve month high of $37.99. The firm’s 50-day simple moving average is $28.80 and its 200-day simple moving average is $27.23.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The business had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. On average, equities analysts forecast that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $60.00 price target on shares of Septerna in a report on Tuesday, March 10th. Truist Financial boosted their price objective on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Raymond James Financial raised their target price on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a report on Monday, June 8th. Guggenheim assumed coverage on shares of Septerna in a research report on Thursday, June 11th. They set a “buy” rating and a $52.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $45.78.

Institutional Investors Weigh In On Septerna

Several large investors have recently made changes to their positions in SEPN. Deutsche Bank AG grew its holdings in Septerna by 5.3% during the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after purchasing an additional 744 shares during the period. Global Retirement Partners LLC bought a new stake in shares of Septerna in the fourth quarter valued at about $35,000. JPMorgan Chase & Co. grew its stake in shares of Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares in the last quarter. PharVision Advisers LLC grew its position in Septerna by 17.5% during the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after buying an additional 1,780 shares in the last quarter. Finally, Nuveen LLC grew its position in Septerna by 7.7% during the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after buying an additional 1,837 shares in the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.